|Bid||41.50 x 1400|
|Ask||44.10 x 900|
|Day's Range||42.02 - 44.85|
|52 Week Range||39.07 - 65.51|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
PTC Therapeutics spiked Wednesday after an analyst suggested it and Roche could rout Biogen and Ionis Pharmaceuticals in treating spinal muscular atrophy.
PTC Therapeutics shares are spiking following intriguing trial data; however, it's not the only competitor working on better treatments for SMA.
Biogen and Ionis Crash on PTC Therapeutics' Promising DataPTC Therapeutics presented positive data on its SMA drug under trial
Mid-caps stocks, like Ionis Pharmaceuticals Inc (NASDAQ:IONS) with a market capitalization of US$5.85B, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-capRead More...
Biogen (BIIB) completed a pact to collaborate with Ionis Pharmaceuticals (IONS), and bought 11.5 million Ionis shares for $625 million, paying $54.34 each. Biogen also invested $375 million as an upfront payment to Ionis to "jointly discover and develop novel antisense drugs for a broad range of neurological diseases," as stated in a press release. In total, Biogen laid out $1 billion in cash.
Editas has key collaboration agreements with Juno Therapeutics and Allergan Pharmaceuticals. Of the nine analysts covering Editas Medicine in May, five have given the stock “buy” or higher ratings, three have given it “hold” ratings, and one has given it a “strong sell” rating. The mean rating for the stock is 2.67, and its target price is $45.2, implying an upside potential of 23.4% over its closing price of $36.63 on May 24.
In the first quarter, Clovis Oncology’s (CLVS) operating expenses rose YoY (year-over-year) to $100.6 million from $80.4 million, due to a larger net loss and inventories rising. Clovis’s investments fell YoY to $9.8 million from $86.6 million due to the company buying $133 million in available-for-sale securities and selling $50 million in securities in 2017. In the first quarter of this year, Clovis sold $10 million in available-for-sale securities and purchased $217,000 in property and equipment. Clovis generated $226.9 million from financing activities in the first quarter of 2017.
Clovis Oncology (CLVS) is a biopharmaceutical company with a focus on acquiring, developing, and commercializing anti-cancer agents. Clovis’s Rubraca (rucaparib), launched in the United States in December 2016, is approved for treating adult patients with deleterious BRCA1-mutation epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received two or more chemotherapies. Of the nine analysts covering Clovis Oncology, seven have recommended “buy” or a higher rating, while two have recommended “hold.” Clovis’s target price of $79.57 implies a 67.4% upside based on the stock’s May 24 closing price of $47.52.
In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million. Analysts expect Ionis’s top line to rise ~30.2% to ~$135.7 million in the second quarter. The chart below shows analysts’ recommendations for Ionis stock over the last year.
Ionis Pharmaceuticals’ (IONS) Spinraza (nusinersen) is an FDA-approved drug designed for the treatment of spinal muscular atrophy, a type of severe motor-neuron disease in pediatric patients and adults. Biogen (BIIB), which has held the worldwide development and commercialization rights for Spinraza since January 2012, forwards royalties to Ionis.
In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% YoY (year-over-year) to $144.4 million from $145.3 million. Analysts expect its revenue to grow 30.2% YoY to $135.7 million in the second quarter. The graph below compares Ionis’s revenue since Q1 2017.
How Is Alnylam Pharmaceuticals Positioned in 2018? Since the beginning of 2018, the stock price of Alnylam Pharmaceuticals has dropped from $130 levels to $100 as of May 21. Overall, Alnylam Pharmaceuticals has fallen 24%.
In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million, as shown in the chart below. Ionis’s revenue sources include commercial revenue from Spinraza royalties and other licensing and royalty revenue, as well as research and development revenue under collaborative agreements. Spinraza (nusinersen), approved for the treatment of pediatric and adult patients with spinal muscular atrophy, was developed in collaboration with Biogen (BIIB), which holds Spinraza’s development, manufacturing, and commercializing licenses. Kynamro injections, approved by the FDA for the treatment of homozygous familial hypercholesterolemia, is developed and commercialized by Kastle Therapeutics, a Sanofi (SNY) subsidiary.
Ionis Pharmaceuticals (IONS), a leading therapeutics company, develops and markets drugs for life-threatening diseases. The chart below compares Ionis’s revenue and EPS since Q1 2017. In the first quarter, Ionis’s revenue rose ~24.7% year-over-year to $144.4 million from $115.8 million.
How Is Alnylam Pharmaceuticals Positioned in 2018? Alnylam Pharmaceuticals (ALNY) is a global biopharmaceutical company focused on developing RNA interference-based novel therapeutics. Alnylam is harnessing this pathway to develop a new class of innovative medicines called RNAi therapeutics.
Uniqure NV (NASDAQ: QURE ) has managed to win the seal of approval from Wells Fargo Securities due to its gene therapy pipeline candidates that target multiple diseases. The Analyst Analyst Jim Birchenough ...
We are closing in on the end of another week in the biotechnology space just as was the case last week, we’ve seen plenty of movement in the sector on the back of a number of fresh releases. Here is a look at the most pertinent and a description of what it means for the […] The post Akcea and Ionis Just Got A Major Boost appeared first on Market Exclusive.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.